Journal of Neuro-Oncology

, Volume 64, Issue 3, pp 271–278 | Cite as

Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity

  • Brian Thiessen
  • John A. Maguire
  • Kelly McNeil
  • David Huntsman
  • Montgomery A. Martin
  • Doug Horsman


Oligodendroglial tumors frequently have deletions of chromosomal loci on 1p and 19q. Loss of heterozygosity (LOH) of chromosome 10 may be a negative prognostic factor. We reviewed 23 patients with oligodendroglial tumors, to evaluate the frequency of 1p and 10q LOH and correlate with clinical outcome. Three loci (D1S402, D1S1172, MCT118) on 1p and 2 loci (D10S520 and D10S521) on 10q were analyzed for LOH using PCR techniques. Sixteen oligodendrogliomas (6 low grade and 10 anaplastic) and 7 oligoastrocytomas (1 low grade and 6 anaplastic) were studied. Overall 14/22 (64%) showed 1p LOH and 7/23 (30%) showed 10q LOH. Of 7 patients with some response to chemotherapy, all showed 1p LOH and none had 10q LOH. Of 5 patients with stable or progressive disease, 1 had 1p LOH and 2 showed 10q LOH. The presence of 1p LOH was significantly associated with response to chemotherapy (p = 0.02). Median progression free survival (PFS) was 31 months for 1p intact patients and 118 months for the 1p LOH group (p = 0.014). Median PFS for 10q LOH patients was 31 and 118 months for patients with intact chromosome 10 (p = 0.016). 1p LOH is a predictor of response to chemotherapy and a good prognostic factor. 10q LOH is less common in oligodendroglial tumors but predicts for worse outcome. Molecular genotyping of oligodendroglial tumors is recommended as part of the standard diagnostic workup.

chemotherapy chromosome 1p chromosome 10q oligodendroglioma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresona J, Pestafia A, Rey JA: Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57: 172–175, 1994Google Scholar
  2. 2.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473–1479, 1998Google Scholar
  3. 3.
    Kraus JA, Koopman J, Kaskel P, Maintz D, Bradner S, Schramm J, Louis DN, Wiestler OD, von Diemling A: Shared allelic loss on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropath Exp Neurol 54: 91–95, 1995Google Scholar
  4. 4.
    Kros JM, van Run PRWA, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJJ, van Decken H: Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization. J Pathol 188: 282–288, 1999Google Scholar
  5. 5.
    Smith JS, Perry A, Borell TJ, Lee HK, O'Falloon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin Oncol 18: 636–645, 2000Google Scholar
  6. 6.
    James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavanee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546–5551, 1988Google Scholar
  7. 7.
    Fults D, Brockmeyer, D, Tullous MW, Pedone CA, Cawthon RM: p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 52: 674–679, 1992Google Scholar
  8. 8.
    Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN: Molecular subtypes of anaplastic oligodendrogliomas: implications for patient management at diagnosis. Clin Cancer Res 7: 839–845, 2001Google Scholar
  9. 9.
    Sasaki H, Zlatescu ML, Betensky RA, Ino Y, Cairncross JG, Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendroglioma and PTEN alterations are associated with poor prognosis. Am J Pathol 159: 359–367, 2001Google Scholar
  10. 10.
    Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre JY, Poirier J, Broet P, Sanson M: Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57: 1278–1281, 2001Google Scholar
  11. 11.
    Bigner SH, Matthews MR, Rasheed BKA, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155: 375–386, 1999Google Scholar
  12. 12.
    Jeuken JWM, Nelen MR, Vermeer H, van Staveren WCG, Kremer H, vanOverbeeke JJ, Boerman RH: PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors: PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 119: 42–47, 2000Google Scholar
  13. 13.
    Daumas-Duport C, Varlet P, Tucker M-L, Beuvon F, Cervera P, Chodkiewicz J-P: Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 34: 37–59, 1997Google Scholar
  14. 14.
    Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335–350, 1987Google Scholar
  15. 15.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of malignant glioma. J Clin Oncol 8: 1277–1280, 1990Google Scholar
  16. 16.
    Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48: 825–830, 2000Google Scholar
  17. 17.
    Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN: Histopathologicalmolecular genetic correlations in referral pathologistdiagnosed low-grade ‘oligodendroglioma’. J Neuropath Exp Neurol 61: 58–63, 2002Google Scholar
  18. 18.
    Pohl U, Cairncross JG, Louis DN: Homozygous deletions of the CDKN2C/p18 gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 9: 639–643, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Brian Thiessen
    • 1
    • 2
  • John A. Maguire
    • 3
  • Kelly McNeil
    • 4
  • David Huntsman
    • 4
  • Montgomery A. Martin
    • 5
  • Doug Horsman
    • 4
  1. 1.Department of Medical OncologyBritish Columbia Cancer AgencyCanada
  2. 2.Division of Neurology, Department of MedicineCanada
  3. 3.Division of Neuropathology, Department of PathologyVancouver General HospitalVancouverCanada
  4. 4.Department of PathologyBritish Columbia Cancer AgencyVancouverCanada
  5. 5.Department of Diagnostic ImagingBritish Columbia Cancer AgencyVancouverCanada

Personalised recommendations